GLP-3RT (Retatrutide)
A novel triple agonist (GLP-1/GIP/glucagon) studied in laboratory and clinical settings for metabolic regulation
About GLP-3RT (Retatrutide)
GLP-3RT (also known as Retatrutide, CAS 2381089-83-2) is a novel triple agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Preclinical and Phase 2 clinical research has examined its interactions with three complementary metabolic signaling pathways, with Phase 2 trial data published in the New England Journal of Medicine and The Lancet.
GLP-3RT is a triple receptor agonist that binds GLP-1R, GIPR, and GCGR with engineered selectivity ratios. Researchers use this compound to study the interplay between incretin and glucagon receptor signaling pathways in cellular and in-vitro metabolic models.
Its triple-agonist profile provides a unique tool for investigating how simultaneous activation of these three receptor systems affects downstream intracellular signaling cascades. The engineered potency ratios across GLP-1R, GIPR, and GCGR allow researchers to probe receptor crosstalk and pathway integration that cannot be studied with single- or dual-agonist compounds.
GLP-3RT has generated significant scientific interest as a pharmacological tool for incretin receptor research following the publication of Phase 2 clinical trial data in the New England Journal of Medicine (2023) and The Lancet (2023) examining its effects on body weight and glycemic control.
Quick Facts
| CAS Number | 2381089-83-2 |
|---|---|
| Molecular Formula | C₂₂₅H₃₄₈N₆₀O₆₈S |
| Molar Mass | 5104.6 g/mol |
| Sequence | 39 amino acids |
| Form | Lyophilized powder |
| Purity | 99%+ (HPLC verified) |
| Third-Party Testing | Freedom Diagnostics (COA included) |
| Storage | Room temp 3–4 months; refrigerate post-reconstitution |
| Price (from) | $100.00 USD |
| SKU | PF-GLP3RT |
How GLP-3RT (Retatrutide) Works
Preclinical and clinical studies have examined GLP-3RT's unique mechanism as the first triple agonist engaging GLP-1, GIP, and glucagon receptors simultaneously for synergistic metabolic effects.
GLP-1 Receptor Activation
GLP-3RT activates GLP-1 receptors on pancreatic beta cells and in the CNS. This stimulates glucose-dependent insulin secretion, suppresses appetite through hypothalamic signaling, and slows gastric emptying to reduce post-meal glucose excursions in clinical research.
GIP Receptor Agonism
GIP receptor activation enhances insulin secretion and promotes adipocyte lipid storage efficiency. In combination with GLP-1 agonism, GIP signaling may improve beta cell function and contribute to improved glucose tolerance and metabolic flexibility.
Glucagon Receptor Engagement
Unlike other incretins, glucagon receptor activation increases hepatic fatty acid oxidation, stimulates thermogenesis, and elevates energy expenditure. This provides an additional mechanism for reducing body fat beyond appetite suppression alone.
Triple Synergy
The three receptor systems work synergistically: GLP-1 and GIP enhance insulin secretion while GLP-1 suppresses glucagon's hyperglycemic effects. Meanwhile, glucagon's thermogenic actions complement the appetite-suppressing effects of GLP-1 for comprehensive metabolic modulation.
Frequently Asked Questions
- What is GLP-3RT (Retatrutide)?
- GLP-3RT (also known as Retatrutide, CAS 2381089-83-2) is a novel triple agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Preclinical and Phase 2 clinical research has examined its interactions with three complementary metabolic signaling pathways, with Phase 2 trial data published in the New England Journal of Medicine and The Lancet.
- What is the CAS number for GLP-3RT (Retatrutide)?
- The CAS number for GLP-3RT (Retatrutide) is 2381089-83-2.
- What purity is Peptide Foundry's GLP-3RT (Retatrutide)?
- Peptide Foundry's research peptides are manufactured to 99%+ purity. Every batch is verified by an independent third-party laboratory (Freedom Diagnostics) using high-performance liquid chromatography (HPLC) for purity and identity, Limulus amebocyte lysate (LAL) assay for bacterial endotoxin, and inductively coupled plasma mass spectrometry (ICP-MS) for heavy-metal contamination. A Certificate of Analysis is published for every product and batch.
- How should GLP-3RT (Retatrutide) be stored?
- Lyophilized (freeze-dried) peptides are stable at room temperature for 3–4 months. Once reconstituted with bacteriostatic water, store refrigerated (2–8 °C) and use within 30 days. Keep away from direct light and extreme temperatures.
- Does GLP-3RT (Retatrutide) ship with a Certificate of Analysis?
- Yes. Every batch of every product ships with a Certificate of Analysis from Freedom Diagnostics, an independent third-party analytical laboratory. The COA documents HPLC purity, peptide identity, endotoxin testing, and heavy-metals screening.
- Is GLP-3RT (Retatrutide) sold for human use?
- No. All products sold by Peptide Foundry are strictly for in-vitro research and laboratory use only (RUO). They are not intended for human or animal consumption, therapeutic use, or diagnostic application.
Scientific References
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247. PubMed: 35985340
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. PubMed: 37366315
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet. 2023;402(10401):529-544. PubMed: 37385280
- Loomba R, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30(7):2024-2033. PubMed: 38858523
This product is sold strictly for in-vitro research use only (RUO). It is not intended for human or animal consumption, therapeutic use, or diagnostic application.